8-K: Adagio Medical Appoints Todd Usen as CEO, Olav Bergheim Steps Down

Adagio Medical Holdings has appointed Todd Usen as its new CEO and director, succeeding founder Olav Bergheim, who will transition to an advisory role.

Summary

• Adagio Medical Holdings announced the departure of its founder and CEO, Olav Bergheim, effective December 13, 2024.
• Todd Usen has been appointed as the new CEO and a Class I director, also effective December 13, 2024.
• Orly Mishan, a current director, has been appointed as the chairperson of the Board, effective December 13, 2024.
• Bergheim will serve as an advisor for 12 months following his resignation, receiving a stock option for 338,398 shares and a total of $1,500,000 in cash severance, with $300,000 contingent on a change in control or successful financing.
• Usen will receive a base salary of $500,000 per year, a potential annual bonus of up to 50% of his base salary, and a financing bonus of 16% of his base salary, contingent on a successful financing or business development transaction.
• Usen will also receive an option to purchase shares representing approximately 5% of the company's fully diluted shares outstanding.
• The company has issued a press release on December 16, 2024, regarding these changes.

Sentiment

Score: 7

Explanation: The document presents a planned leadership transition with a positive outlook for the future. The appointment of an experienced CEO is a positive development, but the departure of the founder and the contingent nature of some compensation elements introduce some uncertainty.

Positives

• The company has secured an experienced medical device executive, Todd Usen, as its new CEO.
• Usen has a proven track record of leading large, complex global businesses and has experience in restructuring and growing companies.
• Bergheim will remain as an advisor to ensure a smooth transition.
• The company has a clear plan for executive compensation and incentives for the new CEO.

Negatives

• The departure of the founding CEO, Olav Bergheim, may create uncertainty.
• The company is incurring significant severance costs for the outgoing CEO, totaling $1,500,000 in cash, plus stock options.
• The new CEO's financing bonus is contingent on raising a minimum of $30,000,000 or an amount equal to the projected cash runway until six months after top line data from the FULCRUM Phase 3 clinical trial, which may be challenging.

Risks

• The transition in leadership could disrupt the company's operations and strategic direction.
• The company's ability to secure the necessary financing to trigger the new CEO's bonus is uncertain.
• The company is reliant on the success of the FULCRUM Phase 3 clinical trial, which is still ongoing.
• The company faces competition in the medical device industry.

Future Outlook

The company anticipates continued success with the new leadership and is focused on commercial efforts in Europe and the FULCRUM-VT trial in the United States. They believe their technology will become the future standard of care for ventricular tachycardia.

Management Comments

• Orly Mishan stated that the company is grateful for Olav's contributions and fortunate to add Todd Usen to the team.
• Todd Usen expressed excitement about joining Adagio and supporting its commercial efforts and clinical trials.
• Olav Bergheim stated he is proud of what the company has accomplished and confident in its continued success.

Industry Context

This announcement reflects a significant leadership change in a medical device company focused on innovative cryoablation technology. The appointment of a new CEO with a strong commercial background suggests a shift towards scaling and commercializing their products. This is a competitive space with other companies developing similar technologies.

Comparison to Industry Standards

• The severance package for Olav Bergheim is substantial, but not uncommon for a founding CEO of a publicly listed company.
• Todd Usen's compensation package is competitive with other CEOs in the medical device industry, with a mix of base salary, bonus potential, and equity incentives.
• Usen's previous experience at Minerva Surgical, Activ Surgical, and Olympus Corporation is relevant to Adagio's stage of development.
• The company's focus on the FULCRUM-VT trial is consistent with the industry's emphasis on clinical evidence to support regulatory approvals and market adoption.

Management Changes

Stakeholder Impact

• Shareholders may react to the leadership change and the associated costs.
• Employees will be impacted by the change in leadership and potential strategic shifts.
• Customers and partners may be affected by any changes in the company's direction.
• The company's creditors may be impacted by the company's financial performance and ability to raise capital.

Next Steps

• Todd Usen will assume his role as CEO and director.
• Olav Bergheim will transition to an advisory role.
• The company will continue its commercial efforts in Europe.
• The company will continue enrollment in the FULCRUM-VT trial in the United States.
• The company will seek to secure the necessary financing to trigger the new CEO's bonus and the additional severance payment to the outgoing CEO.

Key Dates

Keywords

CEO, Chief Executive Officer, Medical Device, Executive Transition, Leadership Change, Cryoablation, Cardiac Arrhythmias, Severance, Equity Financing, Board of Directors